Klaus G. Parhofer, Kåre I. Birkeland, Ralph A. DeFronzo, Stefano Del Prato, Amitabha Bhaumik, Agata Ptaszynska,
... study evaluated the effect of 16 weeks of irbesartan vs. hydrochlorothiazide (HCTZ) on insulin resistance as well ... in hypertensive subjects with metabolic syndrome. Patients received irbesartan (150 mg/d; n = 211) or HCTZ (12. ... study (weeks 16–28), patients initially randomised to irbesartan received additional HCTZ and vice versa. Results: At week 16 both irbesartan and HCTZ had no effect on insulin resistance ... the study (week 16–28) no differences between irbesartan and HCTZ with respect to glucose metabolism were ...
Tópico(s): Lipoproteins and Cardiovascular Health
2009 - Wiley | International Journal of Clinical Practice
Joel M. Neutel, Stanley S. Franklin, Amitabha Bhaumik, Pablo Lapuerta, Suzanne Oparil,
... multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic ... Patients were randomized 2:1 to 7 weeks' irbesartan/HCTZ 150/12.5 mg to 300/25 mg (n = 468) or irbesartan 150 mg to 300 mg (n = 227). The ... combined incidence of prespecified AEs was lower with irbesartan/HCTZ than with irbesartan (8.8% vs. 11.5%). There were no ... patients achieved SeDBP < 90 mm Hg compared to irbesartan (47% vs. 33%; P = 0.0005). Despite more ...
Tópico(s): Cardiovascular Syncope and Autonomic Disorders
2009 - Informa | Clinical and Experimental Hypertension
Giuseppe Derosa, Ilaria Ferrari, Arrigo F.G. Cicero,
... increasing the efficacy and safety of RAAS blockers. Irbesartan is a potent and selective angiotensin II subtype ... type 2 diabetes mellitus and nephropathy. Once-daily irbesartan administration provides 24h control of BP. In patients with mild-to-moderate hypertension, irbesartan was as effective as enalapril, atenolol and amlodipine, ... of absolute reduction in BP and response rate. Irbesartan also induced regression of left ventricular hypertrophy. Moreover, irbesartan 300 mg/day exerts a significant renoprotective effect ...
Tópico(s): Hormonal Regulation and Hypertension
2009 - Bentham Science Publishers | Current Vascular Pharmacology
... demonstrate that the orally available angiotensin II antagonist irbesartan reduces arterial pressure and pathological proteinuria, mostly with ... excellent tolerability profile. Little information is available on irbesartan in childhood. A total of 44 pediatric outpatients ... to 18 years, median 10 years) were given irbesartan once a day during 18 weeks for arterial ... 13). In patients with hypertension, the use of irbesartan 4.1 (3.1–5.3) mg/kg ... protein excretion decreased (P < .01) during treatment with irbesartan (2.9 [2.0–4.8] mg/kg ...
Tópico(s): Sodium Intake and Health
2002 - Oxford University Press | American Journal of Hypertension
António Coca, Carlos Calvo, Juan García‐Puig, Blas Gil Extremera, María Teresa Aguilera, Alejandro de la Sierra, Alberto Martín-Hidalgo, Rafael Marín,
... ABPM) to compare the BP-lowering efficacy of irbesartan and enalapril in a large number of patients (> ... with mild to moderate essential hypertension treated with irbesartan or enalapril. The relative tolerability of the 2 ... randomized to 12 weeks of active treatment with irbesartan or enalapril. Starting doses were 150 and 10 ... 238 patients were randomized to treatment, 115 to irbesartan and 123 to enalapril. The study population was ∼ ... study was completed by 111 patients in the irbesartan group (dose titrated to 300 mg/d in ...
Tópico(s): Heart Rate Variability and Autonomic Control
2002 - Elsevier BV | Clinical Therapeutics
Ernesto Bragulat, María Larrousse, António Coca, Alejandro de la Sierra,
... of antihypertensive treatment with the angiotensin receptor blocker irbesartan on endothelial function in a group of essential ... the end of a six-month period of irbesartan treatment. Endothelium-dependent and -independent responses are determined ... at baseline and at the end of treatment. Irbesartan promoted a significant increase in EDV (from 433± ... L-NMMA-induced vasoconstriction was significantly enhanced after irbesartan treatment (relative decrease of FBF from 33.4± ... 001). Plasma concentrations of endothelin fell significantly after irbesartan treatment (from 5.78±1.86 to 4. ...
Tópico(s): Hormonal Regulation and Hypertension
2003 - Taylor & Francis | British Journal of Biomedical Science
Jippe C. Balt, M. J. Mathy, Martin Pfaffendorf, Pieter A. van Zwieten,
... blockade by the selective AT 1 ‐receptor antagonist irbesartan in pithed spontaneously hypertensive rats and normotensive Wistar– ... AT 1 ‐receptors, we studied the effect of irbesartan on the sequelae of electric stimulation of the ... 1 ‐blockers and α‐adrenoceptors, the effects of irbesartan on pressor responses to exogenous noradrenaline (NA) were established. Additionally, we studied the effect of irbesartan on dose–response curves for the vasocontriction induced ... in DBP could be dose‐dependently reduced by irbesartan (0.3–10 mg/kg) in both SHR ...
Tópico(s): Heart Rate Variability and Autonomic Control
2003 - Wiley | Fundamental and Clinical Pharmacology
Elisabetta Cerbai, Petra De Paoli, Laura Sartiani, Giuseppe Lonardo, Alessandro Mugelli,
... hypertrophy; the effect of 8-week treatment with irbesartan, a type 1 angiotensin II receptor (AT(1)) ... month-old hypertensive rats (SHRs) were treated with irbesartan (20 mg/kg/d) or saline for 8 ... weight to body weight ratio were reduced in irbesartan-treated compared with nontreated SHRs. Electrical and contractile ... respectively. Action potential duration was significantly shorter in irbesartan-treated than in nontreated SHRs (at -60 mV: ... correspondingly, maximal I(to) density was larger in irbesartan-treated than in nontreated SHRs (25.4 +/- 2. ...
Tópico(s): Ion channel regulation and function
2003 - Lippincott Williams & Wilkins | Journal of Cardiovascular Pharmacology
Steen Andersen, J. Bröchner‐Mortensen, Hans‐Henrik Parving,
OBJECTIVE—Irbesartan is renoprotective in patients with type 2 diabetes and microalbuminuria. Whether the observed reduction in microalbuminuria is ... is unknown. Therefore, the present substudy of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria ... randomized to double-masked treatment with either placebo, irbesartan 150 mg, or irbesartan 300 mg o.d. for 2 years. Arterial ... RESULTS—Baseline characteristics were similar in the placebo, irbesartan 150-mg, and irbesartan 300-mg groups. At ...
Tópico(s): Diabetes Treatment and Management
2003 - American Diabetes Association | Diabetes Care
Quang T. Nguyen, Federico Colombo, Robert Clément, Hugues Gosselin, Jean‐Lucien Rouleau, Angelino Calderone,
... the rat. The selective AT 1 receptor antagonist irbesartan was administered <10 h following coronary artery ligation, ... was significantly elevated in the NILV and RV. Irbesartan (40 mg kg −1 /day −1 ) administration did ... the 4‐day post‐MI rat. By contrast, irbesartan therapy normalized RVSP (MI+irbesartan=25±1 mm Hg), RVEDP (MI+irbesartan=3±0.3 mm Hg), and reduced ERK1 (MI=3.0±0.6, MI+irbesartan=2.0±0.3‐fold increase), and ERK2 (MI=3.8±0.8, MI+irbesartan=2.2±0.5‐fold increase) phosphorylation. In ... increased prepro‐ANP, and prepro‐BNP mRNA expression. Irbesartan therapy normalized RVSP, attenuated RVEDP, and abrogated natriuretic ...
Tópico(s): Receptor Mechanisms and Signaling
2003 - Wiley | British Journal of Pharmacology
Ignacio Moreno, Ricardo Caballero, Teresa González, Cristina Arias, Carmen Valenzuela, Isabel Iriepa, Enrique J. Galvez, Juan Tamargo, Eva Delpón,
We studied the effects of irbesartan, a selective angiotensin II type 1 receptor antagonist, on human ether-a-go-go -related gene (HERG), KvLQT1+minK, hKv1.5, ... Kv4.3 channels using the patch-clamp technique. Irbesartan exhibited a low affinity for HERG and KvLQT1+ ... 85.4 μM, respectively). In hKv1.5 channels, irbesartan produced two types of block, depending on the concentration tested. At 0.1 μM, irbesartan inhibited the current in a time-dependent manner ( ... at more positive potentials. However, at 10 μM, irbesartan induced a time-independent blockade that occurred in ...
Tópico(s): Receptor Mechanisms and Signaling
2003 - American Society for Pharmacology and Experimental Therapeutics | Journal of Pharmacology and Experimental Therapeutics
Frederik Persson, Peter Rossing, K. J. Schjoedt, Tina R. Juhl, Lise Tarnow, Coen D.A. Stehouwer, Casper G. Schalkwijk, Frans Boomsma, Erik Frandsen, H.-H. Parving,
... 1298Google Scholar Angiotensin II receptor blockers (ARBs) like irbesartan, losartan, and valsartan are standard therapy in patients ... Bröchner-Mortensen J. et al.The effect of irbesartan on the development of diabetic nephropathy in patients ... al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 ... al.Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ... In the IRMA 2 study, 300 mg of irbesartan once daily reduced urinary albumin excretion by 38%. ...
Tópico(s): Receptor Mechanisms and Signaling
2008 - Elsevier BV | Kidney International
Faryal Mirza, Paul Jau Lueng Ong, Peter Collins, Kyoko Okamura, Marie Gerhard‐Herman, Gordon H. Williams, Ellen W. Seely,
... purpose of this study was to determine whether irbesartan, an angiotensin receptor blocker, has a greater effect ... vascular function when combined with estradiol, compared with irbesartan alone, in hypertensive postmenopausal women. Design: Fifty-one ... of four treatment arms for 12 weeks: (1) irbesartan and estradiol, (2) irbesartan and placebo, (3) estradiol and placebo, and (4) ... A significantly larger number of women in the irbesartan and estradiol group had a decrease of 5 ... diastolic blood pressures (P < 0.05) compared with irbesartan alone group. Forearm vascular reactivity was increased significantly ...
Tópico(s): Estrogen and related hormone effects
2008 - Lippincott Williams & Wilkins | Menopause The Journal of The North American Menopause Society
Tatsuo Kobayashi, Yuko Akiyama, Nobuteru Akiyama, Hideaki Katoh, Sachiko Yamamoto, Kenzo Funatsuki, Toru Yanagimoto, Mitsuru Notoya, Kenji Asakura, Toshihiro Shinosaki, Kohji Hanasaki,
Irbesartan, an angiotensin II type 1 receptor blocker has been reported to alleviate metabolic disorder in animal ... effect may be related to the ability of irbesartan to serve as a partial agonist for the ... receptor (PPAR)-γ, the target tissues on which irbesartan acts remain poorly defined. As muscle glucose transport ... systemic glucose homeostasis, we investigated the effect of irbesartan on glucose uptake in skeletal muscle cells. In C2C12 myotubes, 24-h treatment with irbesartan significantly promoted both basal and insulin-stimulated glucose ...
Tópico(s): Peroxisome Proliferator-Activated Receptors
2010 - Elsevier BV | European Journal of Pharmacology
Andrew Palmer, William J. Valentine, Joshua Ray,
... the study was to determine the impact of irbesartan treatment on life expectancy (LE), costs and progression ... antagonists and dihydropyridine calcium-channel blockers), (ii) ‘early irbesartan’ 300 mg daily and (iii) ‘late irbesartan’ 300 mg daily (started when overt nephropathy developed). ... probabilities determining nephropathy progression were taken from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other published sources. ... 4% ± 0.7 in patients treated with early irbesartan compared with late irbesartan and control respectively. Early ...
Tópico(s): Diabetes Treatment and Management
2007 - Wiley | International Journal of Clinical Practice
Bi-cheng Liu, Hui-ling Xia, Ji-ning Wu, Xiaoliang Zhang, Dian-ge Liu, Yu-xiang Gong,
Irbesartan, a new antagonist of the type 1 angiotensin II receptor, has been proven to be renal ... still uncertain. Here we investigated the influence of irbesartan on the expression of the integrin-linked kinase ( ... n=20), UUO (n=40), and UUO with irbesartan treatment (UUO+irbesartan, n=40). Irbesartan was given at a dose of 50 mg/ ... surgery, which was significantly decreased by treatment with irbesartan (P<0.01, respectively). The expression of alpha- ... at d 3 after the surgery. Treatment with irbesartan significantly abrogated such effects (P<0.01). The ...
Tópico(s): Kidney Stones and Urolithiasis Treatments
2007 - Springer Nature | Acta Pharmacologica Sinica
Doug Coyle, Roger A. Rodby, Steven Soroka, Adeera Levin, Norman Muirhead, Paul René de Cotret, Roland Chen, Andrew Palmer,
Background: The Irbesartan in Reduction of Microalbuminuria trial and the Irbesartan in Diabetic Nephropathy Trial found that irbesartan is renoprotective in patients having hypertension with type ... this study was to assess whether treatment with irbesartan is cost-effective in Canada relative to conventional ... receptor antagonists (AIIRAs); (2) the early addition of irbesartan (an AIIRA) to conventional treatment; and (3) the late addition of irbesartan to conventional treatment. A Markov model was used ...
Tópico(s): Blood Pressure and Hypertension Studies
2007 - Elsevier BV | Clinical Therapeutics
G. Bakris, Luís M. Ruilope, Francesco Locatelli, Agata Ptaszynska, Burkert Pieske, Jacques de Champlain, Michael A. Weber, Itamar Raz,
... system reduce microalbuminuria regardless of diabetic status. The Irbesartan in the Management of PROteinuric patients at high ... randomized to 20 weeks treatment with ramipril plus irbesartan or to ramipril plus placebo. Patients discontinued or ... week 20 baseline geometric ratios for ramipril plus irbesartan and ramipril plus placebo were not significantly different. ... system reduce microalbuminuria regardless of diabetic status. The Irbesartan in the Management of PROteinuric patients at high ... randomized to 20 weeks treatment with ramipril plus irbesartan or to ramipril plus placebo. Patients discontinued or ...
Tópico(s): Renal and Vascular Pathologies
2007 - Elsevier BV | Kidney International
Lieven Annemans, Nadia Demarteau, Shanlian Hu, Tae‐Jin Lee, Z Morad, Thanom Supaporn, Wu–Chang Yang, Andrew Palmer,
... diabetic nephropathy, has increased globally, especially in Asia. Irbesartan treatment delays the progression of kidney disease at ... This study assessed the cost-effectiveness of early irbesartan treatment in Asian settings.An existing lifetime model was reprogrammed in Microsoft Excel to compare irbesartan started at an early stage to irbesartan or amlodipine started at a late stage, and ... probabilistic sensitivity analysis was performed.Early use of irbesartan yielded the largest clinical and economic benefits reducing ...
Tópico(s): Blood Pressure and Hypertension Studies
2007 - Elsevier BV | Value in Health
... carried out an unplanned subgroup analysis of the Irbesartan in Heart Failure with Preserved Systolic Function (I- ... evaluated the effect of the angiotensin receptor blocker irbesartan in patients with HFPEF. Patients with N-terminal ... failure, and this risk was not affected by irbesartan (placebo, 23.7%; irbesartan, 27.0%). In contrast, patients with lower levels ... in risk (to 6.6%) if treated with irbesartan. Amazingly, >90% of the patients in the low ... or had class III or IV symptoms. Thus, irbesartan reduced the risk of heart failure events only ...
Tópico(s): Cardiac Valve Diseases and Treatments
2011 - Lippincott Williams & Wilkins | Circulation Heart Failure
Shanqun Jiang, Yi-Hsiang Hsu, Scott A. Venners, Yan Zhang, Houxun Xing, Xiaobin Wang, Xiping Xu,
Background To investigate the interactive effect of plasma irbesartan concentration and angiotensin II type 1 receptor (AGT1R) gene polymorphisms on blood pressure (BP) response to irbesartan treatment. Methods This study included 1049 Chinese hypertensive ... who were treated with daily oral 150 mg irbesartan for 4 weeks. BP at predose and 28th day of treatment and trough plasma irbesartan concentration (on 28th day of treatment) were measured. ... were used to assess interactive effect of plasma irbesartan concentration and gene polymorphisms on BP response, with ...
Tópico(s): Blood Pressure and Hypertension Studies
2011 - Lippincott Williams & Wilkins | Journal of Hypertension
Ruixin Ma, Jing Yu, Dian Xu, Longquan Yang, Xin Lin, Feng Zhao, Feng Bai,
To evaluate the impact of felodipine with irbesartan on sexual function compared with felodipine with metoprolol in hypertensive women.This was a prospective, randomized, parallel, active-controlled, open-label study (ClinicalTrials. ... a once-daily treatment with felodipine combined with irbesartan or metoprolol for 48 weeks. Patients' sexual function ... lowering blood pressure. After 48 weeks, in felodipine-irbesartan group, total scores of FSFI improved (P < 0. ... Levels of estradiol increased under treatment with felodipine-irbesartan (P = 0.003) and decreased under felodipine-metoprolol ...
Tópico(s): Hormonal and reproductive studies
2011 - Lippincott Williams & Wilkins | Journal of Hypertension
Salim Yusuf, Jeff S. Healey, Janice Pogue, Susan Chrolavicius, Marcus Flather, Robert G. Hart, Stefan H. Hohnloser, Campbell Joyner, Marc A. Pfeffer, Stuart J. Connolly,
... with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk. ... at least 110 mm Hg to receive either irbesartan at a target dose of 300 mg once ... was 2.9 mm Hg greater in the irbesartan group than in the placebo group, and the ... person-years in both groups (hazard ratio with irbesartan, 0.99; 95% confidence interval [CI], 0.91 ... 3% per 100 person-years among patients receiving irbesartan and 7.7% per 100 person-years among ... 7% per 100 person-years among patients receiving irbesartan and 3.2% per 100 person-years among ...
Tópico(s): Antiplatelet Therapy and Cardiovascular Diseases
2011 - Massachusetts Medical Society | New England Journal of Medicine
... hypertension, the efficacy and safety of treatment with irbesartan/hydrochlorothiazide (HCTZ) and irbesartan was assessed in 2 separate analyses: patients with ... and by obesity status (n = 1125). Patients received irbesartan/HCTZ (150 mg/12.5 mg titrated to 300 mg/25 mg) or irbesartan (150 mg titrated to 300 mg) for 7 ( ... and 21.8/15.8 mm Hg after irbesartan/HCTZ and irbesartan treatment, respectively (P [SBP] = 0.09, P [DBP] = ... and 20.1/15.9 mm Hg after irbesartan/HCTZ and irbesartan treatment, respectively (P < 0.0001). ...
Tópico(s): Pharmacology and Obesity Treatment
2011 - Taylor & Francis | Postgraduate Medicine
Martin Busch, Sybille Franke, Günter Wolf, A Brandstädt, U. Ott, Jens Gerth, Lawrence G. Hunsicker, G Stein,
... with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 ± ... with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 ± ... of this prospective study of patients in the Irbesartan in Diabetic Nephropathy Trial (IDNT) cohort is to ... examine the effectiveness of antihypertensive treatment based on irbesartan, amlodipine, or placebo plus other antihypertensive drugs.8Rodby ... R.D. Lewis E.J. Collaborative Study GroupThe Irbesartan type II Diabetic Nephropathy Trial: Study design and ...
Tópico(s): Natural Antidiabetic Agents Studies
2006 - Elsevier BV | American Journal of Kidney Diseases
Andrew Palmer, William J. Valentine, Daniel M. Tucker, Joshua Ray, Stéphane Roze, Lieven Annemans, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita, Roger A. Rodby, Dick de Zeeuw, Hans‐Henrik Parving, Maurice Laville,
... a French setting of the renoprotective benefit of irbesartan in hypertensive type 2 diabetes patients over a ... calcium channel blockers) initiated at microalbuminuria; (B) early irbesartan--(300 mg daily added to control, initiated with microalbuminuria) and (C) late irbesartan--(300 mg daily, initiated with overt nephropathy). Probabilities came from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other sources. Clinical ... were 3%.Compared to control, early use of irbesartan added (mean +/- standard deviation) 1.51 +/- 0.08 ...
Tópico(s): Pharmaceutical Economics and Policy
2006 - Taylor & Francis | Current Medical Research and Opinion
... the effects of an AT-II receptor blocker, irbesartan, on NASH using fatty liver Shionogi (FLS)-ob/ ... animal model of human metabolic syndrome-related NASH. Irbesartan (30 mg/kg/day) was orally administered to FLS-ob/ob mice for 12 weeks (irbesartan group). The effects of irbesartan on steatohepatitis were examined using factors including steatosis, ... hepatic hydroxyproline content were significantly lower in the irbesartan group compared to controls. The areas of α- ... 80-positive cells were significantly decreased in the irbesartan group. The percentage of 8-hydroxy-2-deoxyguanosine ( ...
Tópico(s): Hepatocellular Carcinoma Treatment and Prognosis
2012 - Spandidos Publishing | International Journal of Molecular Medicine
Robert Segal, Trinity J. Bivalacqua, Arthur L. Burnett,
... RRP in patients taking a daily dose of irbesartan, an ARB, following RRP. In addition, the use of irbesartan may curb the loss of stretched penile length ... To evaluate retrospectively the potential benefit of administering irbesartan, an angiotensin‐receptor blocker, to improve erectile function ( ... and December 2009 elected to start daily oral irbesartan 300 mg on postoperative day 1 ( n = 17). ... clinically matched cohort consisting of patients who declined irbesartan use served as the control group ( n = 12). ...
Tópico(s): Urinary Bladder and Prostate Research
2012 - Wiley | BJU International
Can Chen, Liang Zheng, Qiang Chen, Zhi-gen Li,
... The aim was to explore the effect of irbesartan combining with emodin on myocardial remodeling in goldblatt ( ... 1C without any drugs; the 2K-1C with Irbesartan (50mg/kg/day); the 2K-1C with Emodin (80mg/Kg/day); and the 2K-1C with Irbesartan and Emodin together for the last eight weeks ... CTGF). Results: Compared with 2K1C group, the 2K1C/Irbesartan group and 2K-1C/Emodin plus Irbesartan group had significantly lower systolic blood pressure and ... TGF-β1 and the mRNA CTGF of 2K1C/Irbesartan group, 2K1C/Emodin group and 2K-1C/Emodin ...
Tópico(s): Apelin-related biomedical research
2012 - Lippincott Williams & Wilkins | Journal of Cardiovascular Pharmacology
Gema Fernández Juárez, José Luño, V. Barrio, Soledad García de Vinuesa, Manuel Praga, Marián Goicoechea, Victoria Cachofeiro, Javier Nieto, Francisco Fernández de Vega, A Tato, Eduardo Gutiérrez,
... inhibitor lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at ... assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = ... the lisinopril group, and 8 (29%) in the irbesartan group reached the primary outcome. HRs were 0. ... 8) for the combination versus the lisinopril and irbesartan groups, respectively. There were no significant differences in ... a benefit of the combination of lisinopril and irbesartan compared to either agent alone at optimal high ...
Tópico(s): Renin-Angiotensin System Studies
2012 - Elsevier BV | American Journal of Kidney Diseases